J clin oncol. 2010 28 27 : 4184-90
WebMay 15, 2004 · Three of the 28 responding patients did not undergo ASCT: 1 patient refused, one patient did not have an adequate number of mobilized stem cells and underwent allogeneic transplantation from his HLA-matched sibling, and one patient, who did not have any mobilized PBPCs even after a repeated attempt with G-CSF alone, was found to have … WebApr 13, 2024 · Patients aged 70 years or older with low-risk breast cancer (BrC), i.e., clinically axillary node-negative, oestrogen and/or progesterone receptor-positive (hormone receptor-positive, HR+) BrC, have a 10-year disease-specific survival rate of about 98% [].This fact notwithstanding and despite their substantial risk of toxicity and adverse medical effects, …
J clin oncol. 2010 28 27 : 4184-90
Did you know?
WebSep 20, 2010 · Journal of Clinical Oncology: Vol 28, No 27 Vol. 28, No. 27, September 20, 2010 EDITORIALS Is It Time to ReSET the Standard for Estrogen Receptor Testing in … WebApr 11, 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, …
WebAug 18, 2024 · J Clin Oncol. 2010;28(27):4184–90. CrossRef PubMed PubMed Central Google Scholar Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2024;38(2):155–65. WebFilter issues by Issue archive. 2024 - Volume 41. 2024 - Volume 40. 2024 - Volume 39. 2024 - Volume 38. 2010 - 2024. 2000 - 2009. 1990 - 1999. 1980 - 1989.
WebMay 1, 2010 · J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. Authors Anne Aupérin 1 , Cecile Le Péchoux, Estelle Rolland, Walter J Curran, Kiyoyuki Furuse, Pierre Fournel, Jose Belderbos, Gerald Clamon, Hakki Cuneyt Ulutin, Rebecca Paulus ... WebJun 8, 2024 · Front. Oncol. 2024; 9: 591. 7 Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J. Clin. Oncol. 2010; 28: 311–7. 8 Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG.
WebJun 8, 2024 · J Clin Oncol. 2010;28 (27):4184–90. (1iiDiv/1iiA). 13. Mey UJ, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as …
WebNov 8, 2011 · DLBCL is a curable disease and combination of monoclonal antibody against CD20 (rituximab) with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen have improved the prognosis of patients with a 20% increase of the cure rate. la mesa jail tijuanaWebJan 7, 2024 · Oncol. 28, 4184–90 (2010). Article Google Scholar Qualls, D. & Abramson, J. S. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. la mesa jobsWebApr 12, 2024 · CA: A Cancer Journal for Clinicians publishes information about the prevention, early detection, and treatment of cancer, as well as nutrition, palliative care, survivorship, and additional topics of interest related to cancer care. la mesa job openingsWebJan 20, 2024 · J Clin Oncol. 2010;28(27):4184–90. Article Google Scholar Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from … assassins 1995 bg audioWeb2 days ago · 1.Introduction 1.1.Immunotherapy for head and neck neoplasms. Head and neck neoplasms are the sixth most common malignant tumors in the world, with approximately 830,000 patients developing head and neck neoplasms each year [1].It is a general term for a class of cancers with a similar incidence and treatment plan, including … la mesa job opportunitiesWebCRS is the most common and well-described toxicity associated with CAR T-cell therapy, occurring in over 90% of patients at any grade, ... J Clin Oncol. 2010;28(27):4184–4190. 25. Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma ... assassins 13WebMar 30, 2024 · Bortezomib, another proteasomal inhibitor, was combined with R-DA-EPOCH in 27 patients with R/R DLBCL with 83% ORR and 42% CRR in non-GCB DLBCL as compared with 13% ORR and 7% CRR in GCB DLBCL. 17 A phase 1 study evaluating ibrutinib in doses up to 840 mg daily in combination with R-ICE in R/R DLBCL showed impressive results … assassins 1991